KR20240014648A - Paenibacillus elgii strain with antibacterial and antifungal activity and a composition comprising a culture solution or extract thereof - Google Patents

Abstract

The present invention relates to an antibacterial, antifungal or antiseptic composition comprising a Pennybacillus elgi strain having antibacterial and antifungal activity, a culture medium or extract thereof, and a method for producing the same. The culture medium or extract of the Pennybacillus elgi strain of the present invention has antibacterial and antifungal activity on bacteria, fungi, yeast, etc., and can be used as an active ingredient in cosmetics, beauty, food preservatives, and preservatives with excellent antibacterial and antifungal effects. By controlling the concentration of pelgipeptin peptide, the active ingredient of the culture extract, the antibacterial, preservative, skin care, and food preservation effects against specific microorganisms can be significantly improved.

Description

Paenibacillus elgii strain with antibacterial and antifungal activity and a composition comprising a culture solution or extract thereof}

It relates to an antibacterial, antifungal or preservative composition comprising a Pennybacillus elg strain having antibacterial and antifungal activity, a culture medium or extract thereof, and a method for producing the same.

Some of the substances that play an important role in the process of maintaining homeostasis of living organisms are physiologically active substances derived from various living organisms. To date, much research is being conducted on numerous bioactive substances, and among them, research on antibacterial substances is a very important area in the fields of life science and medicine.

All living things are known to produce antibacterial substances for survival, and much research is being conducted on microorganisms that produce antibacterial substances. Research is being conducted to develop antibacterial agents using microorganisms that produce antibacterial substances or substances isolated from them. These have been tried for a long time.

Meanwhile, the genus Paenibacillus is a Gram-positive, aerobic, rod-shaped, endospore-forming bacterium. The main characteristic of this group is the secretion of extracellular enzymes under neutral and alkaline growth conditions. Some species can also produce polysaccharides, amino acids and secondary metabolites such as antibiotics, pigments, toxins, enzyme inhibitors, pheromones and plant and animal growth promoters.

Under this background, the present inventors made diligent efforts to discover a strain with excellent antibacterial and antifungal activity, and as a result, Paenibacillus elgii CWL-10 strain secreted a pelgipeptin peptide with excellent antibacterial and antifungal activity. It was confirmed that it is effective and can be usefully used as an antibacterial agent, antifungal agent, preservative, food preservative, feed additive, etc., and the present invention was completed.

The present inventors confirmed that the antibacterial and antifungal activity of the culture medium of Paenibacillus elgii CWL-10 strain or its extract was significantly excellent.

Accordingly, the purpose of the present invention is to provide a Paenibacillus elgii strain having antibacterial and antifungal activity.

Another object of the present invention is to provide an antibacterial or antifungal composition containing a culture medium of the Pennybacillus LGI strain or an extract thereof.

Another object of the present invention is to provide a preservative composition containing a culture medium of Pennybacillus LGI strain or an extract thereof.

Another object of the present invention is to provide a method for producing an antibacterial or antifungal composition comprising a culturing step of culturing the Pennybacillus LGI strain to prepare a culture medium.

Another object of the present invention is to provide an antibacterial or antifungal method comprising treating a subject with an antibacterial and antifungal composition containing a culture medium of a Pennybacillus LGI strain or an extract thereof.

Another object of the present invention is to provide a method for producing a preservative composition including a culturing step of culturing the Pennybacillus LGI strain to prepare a culture medium.

Another object of the present invention is to provide a preservative method including the step of treating an object with a preservative composition containing a culture medium of a Pennybacillus LGI strain or an extract thereof.

Another object of the present invention relates to the antibacterial or antifungal use of the Pennybacillus LGI strain.

Another object of the present invention relates to the preservative use of Pennybacillus LGI strains.

The present invention relates to a preservative composition containing a culture medium of Paenibacillus elgii strain or an extract thereof.

Hereinafter, the present invention will be described in more detail.

One example of the present invention relates to a Paenibacillus elgii strain having antibacterial and antifungal activity.

As a result of analyzing the genes of the strain of the present invention, it was confirmed that it was a strain with high homology to Pennybacillus elgi species, and it was named Pennybacillus elgi CWL-10.

In the present invention, the Pennybacillus elgii strain may be the Paenibacillus elgii CWL-10 strain deposited under the accession number KCTC 14835BP.

In the present invention, the Pennybacillus elgi CWL-10 strain is the first strain isolated and identified from soil. The colonies form circular colonies on TS solid medium, are highly viscous, and are pale yellow in color.

In the present invention, the 16s rRNA of the Pennybacillus elgi strain may include the base sequence of SEQ ID NO: 3.

Another example of the present invention relates to an antibacterial or antifungal composition containing Pennybacillus elgi strain, its culture medium, or its extract as an active ingredient.

Another example of the present invention relates to a preservative composition containing a Pennybacillus elg strain, its culture medium, or its extract as an active ingredient.

In the present invention, the culture medium may be a culture medium, a culture supernatant, or a culture filtrate, but is not limited thereto.

The term “culture medium” in this specification means containing microorganisms after culturing them.

The term “culture supernatant” in this specification refers to the supernatant obtained by removing most microorganisms from the culture medium through centrifugation, and is also referred to as “supernatant.”

The term “culture filtrate” in this specification means that bacteria are completely removed from the culture medium by centrifugation and filtration.

In the present invention, the composition may include a pelgipeptin-based compound.

In the present invention, the pelgipeptin-based compound may be in a linear form, a cyclic form, or a mixture thereof.

In the present invention, the pelgipeptin-based compound consists of Pelgipeptin A, Pelgipeptin B, Pelgipeptin C, Pelgipeptin D, and Pelgipeptin E. It may be one or more types selected from the group, and for example, may include all of pelgipeptin A, pelgipeptin B, pelgipeptin C, pelgipeptin D, and pelgipeptin E.

In the present invention, the composition includes benzoic acid and para-hydroxybenzoic acid, their esters and salts, benzyl benzoate, propionic acid and its salts, salicylic acid ( salicylic acid and its salts, sorbic acid (2,4-hexadienoic acid) and its salts, levulinic acid and its salts, anisic acid and its salts, perillic acid and salts thereof, cinnamic acid and salts thereof, caprylhydroxamic acid, sorbohydroxamic acid, and mixtures thereof. It may be done, but it is not limited to this.

In the present invention, the composition includes 1,3-propanediol, methyl propanediol, 1,2-pentanediol, 1,2-hexanediol (1) ,2-hexanediol), 1,2-octanediol (1,2-octanediol), 1,2-decanediol (1,2-decanediol), 1,5-pentanediol (1,5-pentanediol), 1, 6-hexanediol (1,6-hexanediol), 1,8-octanediol (1,8-octanediol), 1,2-decanediol, ethylhexylglycerin, sorbitan carbide Sorbitan caprylate, triclosan, climbazole, chitosan, farnesol, 2-butyloctanoic acid, 2-benzylheptan-1-ol (2-Benzylheptan-1-ol), glycerol monolaurate, thymol, eugenol, benzyl alcohol, 2-phenyethyl alcohol, 3 -Phenyl propanol (3-phenyl propanol), 2-phenoxyethanol, 1-phenoxy-propan-2-ol (1-phenoxy-propan-2-ol), 3-phenoxypropanol (3 -phenoxypropanol), and benzyloxymethanol (benzyloxymethanol), but may additionally include one or more selected from the group consisting of, but is not limited to this.

In the present invention, the composition further comprises one or more selected from the group consisting of Iturin, Bacillomycin, Fengycin, Surfactin, and lipopeptide. However, it is not limited to this.

In the present invention, antibacterial agents may be directed against Gram-negative and/or Gram-positive bacteria.

In the present invention, Gram-negative and/or Gram-positive bacteria include Enterococcus sp., Staphylococcus sp., Escherichia coli , Klebsiella sp., and Acinetobacter. It may include one or more species selected from the group consisting of Acinetobacter sp., Streptococcus sp., Xanthomonas sp., and Salmonella sp., for example. , Pseudomonas aeruginosa , Salmonella pullorum, Salmonella enteritidis, Salmonella typhimurium, Staphylococcus aureus , Staphylococcus aeruginosa ( Staphylococcus aeruginosa ), Staphylococcus epidermidis , Streptococcus pneumoniae, Streptococcus pyogenes , Corynebacterium diphtheriae , Bacillus anthracis anthracis ), Bacillus subtilis, Streptococcus mutans , Enterococcus facalis , and Clostridium difficile . One or more types of bacteria selected from the group consisting of It may be about, but is not limited to.

In the present invention, the antifungal agent may be against one or more types of fungi selected from the group consisting of molds, yeasts, and mushrooms, for example, Candida sp. , Aspergillus niger , and Aspergillus genus. sp), Fusarium sp., Colletotrichum coccodes , Endothia parasitica, Fusarium graminearum , Fusarium oxysporum ), Raffaelea quercus-mongolicae, Rhizoctonia solani , Sclerotinia homoeocarpa , Taphrina wiesneri, Macna It may be for one or more species selected from the group consisting of Magnaporthe ozyzae and Botrytis cinera , but is not limited thereto.

In the present invention, the composition includes cosmetics, skin cleansers, hair cleansers, vaginal cleansers, bathroom cleaners, cosmetic cleaners, kitchen cleaners, cosmetic preservatives, food preservatives, pharmaceutical preservatives, food additives, feed additives, health functional foods, livestock feed additives, It can be used in industrial disinfectants, industrial preservatives, antibacterial household goods, antibacterial cosmetics, antibacterial foods, and pharmaceutical additives, but is not limited to these.

Another example of the present invention relates to a method for producing an antibacterial and antifungal composition including a culturing step of culturing a Pennybacillus elgi strain to prepare a culture medium.

Another example of the present invention relates to a method for producing a preservative composition including a culturing step of culturing a Pennybacillus elg strain to prepare a culture medium.

In the present invention, the Pennybacillus elgii strain may be the Paenibacillus elgii CWL-10 strain deposited under the accession number KCTC 14835BP.

In the present invention, the 16s rRNA of the Pennybacillus elgi strain may include the base sequence of SEQ ID NO: 3.

Another example of the present invention relates to an antibacterial or antifungal method comprising treating a subject with an antibacterial and antifungal composition containing a culture medium of a Pennybacillus LGI strain or an extract thereof.

Another example of the present invention is to provide a preservative method including the step of treating an object with a preservative composition containing a culture medium of a Pennybacillus LGI strain or an extract thereof.

In the present invention, the Pennybacillus elgii strain may be the Paenibacillus elgii CWL-10 strain deposited under the accession number KCTC 14835BP.

In the present invention, the 16s rRNA of the Pennybacillus elgi strain may include the base sequence of SEQ ID NO: 3.

The present invention relates to an antibacterial, antifungal or antiseptic composition comprising a Pennybacillus elgi strain having antibacterial and antifungal activity, a culture medium or extract thereof, and a method for producing the same. The culture medium or extract of the Pennybacillus elgi strain of the present invention has antibacterial and antifungal activity on bacteria, fungi, yeast, etc., and can be used as an active ingredient in cosmetics, beauty, food preservatives, and preservatives with excellent antibacterial and antifungal effects. By controlling the concentration of pelgipeptin peptide, the active ingredient of the culture extract, the antibacterial, preservative, skin care, and food preservation effects against specific microorganisms can be significantly improved.

Figure 1 shows the results of phylogenetic tree analysis of Paenibacillus elgii CWL-10 strain according to an embodiment of the present invention.
Figure 2 shows the primary sequence structure of pelgipeptin peptides included in the functional metabolites of Paenibacillus elgii CWL-10 strain according to an embodiment of the present invention.
Figure 3 shows the structure of linear pelgipeptin peptides included in the functional metabolites of Paenibacillus elgii CWL-10 strain according to an embodiment of the present invention. (a) linear pelgipeptin A. (b) linear pelgipeptin B, (c) linear pelgipeptin C, (d) linear pelgipeptin D, and (e) linear pelgipeptin E.
Figure 4 shows the structure of cyclic pelgipeptin peptides included in the functional metabolites of Paenibacillus elgii CWL-10 strain according to an embodiment of the present invention. (a) cyclic pelgipeptin A. (b) cyclic pelgipeptin B, (c) cyclic pelgipeptin C, (d) cyclic pelgipeptin D, and (e) cyclic pelgipeptin E.
Figure 5 shows a mass spectrometry spectrum of pelgipeptin peptides, a functional metabolite of Paenibacillus elgii CWL-10 strain, according to an embodiment of the present invention. [(a) linear pelgipeptin and (b) cyclic pelgipeptin]
Figure 6 is a photograph showing the results of evaluating antibacterial activity in an essence formulation against E. coli according to an embodiment of the present invention.
Figure 7 is a photograph showing the results of evaluating antibacterial activity in an essence formulation against S. aureus according to an embodiment of the present invention.
Figure 8 is a photograph showing the results of evaluating antibacterial activity in an essence formulation against P. aeruginosa according to an embodiment of the present invention.
Figure 9 is a photograph showing the results of evaluating antibacterial activity in an essence formulation against Candida albicans according to an embodiment of the present invention.

Hereinafter, the present invention will be described in more detail through the following examples. However, these examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.

Example 1. Culture of Pennybacillus elgi CWL-10 strain

Pennybacillus elgi CWL-10 strain, which has antibacterial activity, was cultured using liquid medium at 37°C and 180 rpm for one day. Then, the main culture was performed at 37°C.

Example 2. Identification of Pennybacillus elgi CWL-10 strain

Identification of the microorganisms cultured in Example 1 was performed using a molecular phylogenetic method through comparison of 16S ribosomal RNA genes. After amplification was performed by performing PCR using the primer set shown in Table 1 below, the amplification product was purified and the base sequence was analyzed (Table 2).

sequence number denomination Sequence list (5'->3') note One 27F AGA GTT TGA TCM TGG CTC AG 2 1492R TAC GGY TAC CTT GTT ACG ACT T

sequence number denomination Sequence list (5'->3') note 3 16S ribosomal RNA gene ATACTCTGCTCAGGACGAACGCTGGCGGCGTGCCTAATACATGCAAGTCGAGCGGACCCTTCGGGGTTAGCGGCGGACGGGGGTGAGTAACACGTAGGCAACCTGCCTGTAAGACTGGGATAACTACCGGAAACGGTAGCTAAGACCGGATAAGTGATTCTCTCGCATGAGAGGATCAAGAAACACGGGGCAACCTGTGGCTTACAGATGGGCCTGCGGCGCATTAGCTAGTTGGTGGGGTAACGGCTCACCAAGGCGACG ATGCGTAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGAGGCAGCAGTAGGGAATCTTCCGCAATGGACGCAAGTCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAGCTCTGTTGCCAGGGAAGAACGTCGTGGAGAGTAACTGCTCTGCGAATGACGGTACCTGAGAAGAAAGCCCCGGCTAACTACGTGCCCAGCAGCCGCGGTAATACG TAGGGGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGCGCGCGCAGGCGGCCGCTTAAGTCTGGTGTTTAAGCCCGAGGCTCAACCTCGGTTCGCACTGGAAACTGGGGTGGCTTGAGTGCAGGAGAGGAAAGCGGAATTCCACGTGTAGCGGTGAAATGCGTAGAGATGTGGAGGAACACCAGTGGCGAAGGCGGCTTTCTGGCCTGTAACTGACGCTGAGGCGCGAAAGCGTGGGAGCAAACAGGATTAGATACCCT GGTAGTCCACGCCGTAAACGATGAGTGCTAGGTGTTAGGGGTTTCGATACCCTTGGTGCCGAAGTAAACACAATAAGCACTCCGCCTGGGGAGTACGCTCGCAAGAGTGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCAGTGGAGTATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCCTCTGAATATCCTAGAGATAGGGTAGGCCTTCGGGACAGAGGAGACAGGTGGTGCATGGTTGT CGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGAACTTAGTTGCCAGCATTGAGTTGGGCACTCTAAGTTGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTACTACAAATGGCCGGTACAACGGGAAGCGAAGTCGCGAGATGGAGCCAATCCTAAAAAGGCCGGTCTCAGTTCGGATTGCAGGCTGCAACTCG CCTGCATGAAGTCGGAATTGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCACGAGAGTTTACAACACCCGAAGTCGGTGGGGTAACCGCAAGGAGCCAGCCGCCGAAGGTGGGGTAGATGATTGGGGGTGAAGTCGTAACAAGGTAGCCGTATCGGAAGGTGCGGCTGGATCACCT

As a result of homology analysis using the gene bank's Blast program, it showed 99% homology with the species Paenibacillus elgii , and the phylogenetic tree showing the molecular phylogenetic position was Same as Figure 1.

It was named Paenibacillus elgii CWL-10, and was registered with the Korea Research Institute of Bioscience and Biotechnology (KCTC) as of December 20, 2021. Deposit and accession number Was granted KCTC 14835BP.

Example 3. Preparation of CWL-10 culture fluid extract (PGPs mix) using reverse-phase HPLC

To isolate and purify the antibacterial activity metabolites of the Pennybacillus elg CWL-10 strain, the Pennybacillus elg CWL-10 strain was cultured in the same manner as in Example 1 to obtain 500 mL of culture medium. The obtained culture was centrifuged at 4,000 rpm for 15 minutes to obtain a culture supernatant from which the bacterial cells were completely removed. A C18 reversed-phase HPLC column (Shimadzu ODS, 25 x 300 mm) was used. Solvent A (H ₂ O, 0.05% trifluoroacetic acid) and solvent B (CH ₃ CN, 0.05% trifluoroacetic acid) were used, and purification was performed under conditions of solvent B concentration gradient of 5 - 95% for 45 minutes. After purification, it was freeze-dried and used in experiments.

Example 4. Confirmation of antibacterial effect of Pennybacillus elegans CWL-10 culture extract

To confirm the antibacterial effect of the Phenibacillus culture broth extract (PGPmix) containing the pelgipeptin peptide prepared in Example 3, the minimum inhibitory concentration against Gram-negative bacteria, Gram-positive bacteria, yeast, and mold was measured.

Specifically, in the case of bacteria, the bacteria were inoculated into LB (Luria-Bertani) medium and pre-cultured at 37°C for 24 hours, and in the case of yeast, the bacteria were inoculated in YPD (yeast extract-peptone-dextrose) medium. is inoculated and pre-cultured at 37°C for 24 hours. Fungi are inoculated onto potato dextrose agar and pre-cultured at 25°C for 5 days, and then spores formed on the surface of the medium are recovered. It was diluted in potato dextrose medium.

The extract prepared in Example 3 was serially diluted in a 96-well plate so that the final concentrations were 64, 32, 16, 8, 4, 2, 1, and 0.5 μg/ml, respectively. Each pre-cultured test bacteria was diluted to a final concentration of approximately 2×10 ⁶ CFU/mL for bacteria and yeast, and approximately 1×10 ⁵ spores/mL for mold, and loaded in 100 μl each. Bacteria were cultured in an incubator at 37°C for 16 hours, yeasts were cultured in a 30°C incubator for 24 hours, and molds were cultured in a 25°C incubator for 3 days to determine the lowest inhibitory concentration value. The experiment was repeated 3 times each.

There were 11 strains used for the antibacterial effect, and the minimum growth inhibitory concentration (MIC) for representative Gram-negative bacteria, Gram-positive bacteria, yeast, and mold from the cultured extract of Pennybacillus Elgi CWL-10 is shown in Table 2 below.

strain Strain number Minimum growth inhibitory concentration (MIC) (ug/mL) Gram negative bacteria Escherichia coli KCTC 1682 4 Pseudomonas aeruginosa KCTC 1637 16 Gram positive bacteria Staphylococcus aureus KCTC 1621 16 Bacillus subtilis KCTC 3068 2 Yeast Candida glabrata KCTC 7219 16 Candida glabrata ATCC 2001 16 Candida glabrata ATCC 90030 4 Candida albicans ATCC MYA-2876 16 Candida albicans ATCC 90028 8 Candida albicans ATCC 64550 32 Fungi Aspergillus niger KACC 40277 8

As can be seen in Table 3, the antibacterial effect of the PGPmix prepared in Example 3 was measured and the minimum inhibitory concentration for bacteria was 2 to 16 ug/mL. Regarding the yeast Candida, there was a difference in the degree of activity depending on the strain number, but it showed excellent anti-Candida activity with a minimum inhibitory concentration of 4 to 32 ug/mL. It showed strong antifungal activity against Aspergillus niger mold with a minimum inhibitory concentration of 8 ug/mL.

Example 5. Analysis of antibacterial and antifungal active metabolites

High-performance liquid chromatography (Agilent 1100 series, USA) and mass spectrometry (API 3200 Q TRAP, AB Sciex, USA) were used to analyze metabolites with antibacterial and antifungal activity derived from the Pennybacillus elgi CWL-10 strain.

Specifically, the stationary phase column uses X-bridge C18 (2.1 was used. Acetonitrile concentration was flowed at a concentration gradient of 0.2 mL per minute for 22.5 minutes from 5 to 95% by volume (v/v), and the wavelength was 230 nm. The type and molecular weight of pelgipeptin contained in the culture extract of Pennybacillus elgi CWL-10, which was the result of analyzing the antibacterial activity fraction, are shown in Table 4 below. The antibacterial activity of each fraction was confirmed for its antibacterial activity through a disk diffusion test.

peptide m/z , Da Linear Pelgipeptin A 1090.9 Pelgipeptin B 1119.1 Pelgipeptin C 1105.0 Pelgipeptin D 1105.0 Pelgipeptin E 1090.9 Cyclic Pelgipeptin A 1073.9 Pelgipeptin B 1102.4 Pelgipeptin C 1088.0 Pelgipeptin D 1088.0 Pelgipeptin E 1073.9

As can be seen in Table 4, the Pelgipeptin family molecular weight between m/z 1073 and 1119 was detected. Pepeptin peptide is known to be expressed in Pennybacillus algae, and its molecular weight was also compared and analyzed in previous studies. Specifically, as shown in Figure 2, these are lipopeptides in which 9 amino acids (Amino acids) and a short fatty acid (Fatty acid) are linked by an ester bond, and show structural differences depending on the length and shape of the fatty acids.

In the Pennybacillus elgi CWL-10 strain fraction, the linear form in which the ester bond was hydrolyzed (Figure 3) and the cyclic lipopeptide form (Figure 4) were found simultaneously, and the molecular weight detected in the fraction was is shown in Figure 5. The structures of all pelgipeptins were confirmed through amino acid sequence analysis using LC-MS/MS, and pelgipeptins C and E were confirmed through nuclear magnetic resonance (NMR) experiments.

As can be seen in Figures 5a and 5b, molecular weights of m/z 1090.9, 1105.0, and 1119.1 (hereinafter referred to as linear) and 1073.9, 1088.0, and 1102.4 (hereinafter referred to as cyclic) were detected, and this strain contains the lipopeptide and is antibacterial. And it was confirmed that it exhibits antifungal activity.

Example 6. Comparison of antibacterial and antifungal activities with propylene glycols

In order to confirm the antibacterial and antifungal effects of propylene glycol, which is used as a solvent for cosmetic raw materials, a binder and medium for raw material mixing, softeners, moisturizers, food additives, etc., the lowest inhibitory concentration measurement performed in Example 4 was performed in the same manner. .

Specifically, the three types of propylene glycol used to measure antibacterial and antifungal effects are monopropylene glycol (MPG), dipropylene glycol (DPG), and tripropylene glycol. (Tripropylene glycol, TPG) was used. Samples were prepared by diluting three types of propylene glycol to final concentrations of 50, 40, 30, 20, 15, 10, and 5% in a 96-well plate, and the next five strains were prepared in Example a. The same conditions were performed.

The minimum growth inhibition concentration of propylene glycol for strains used for antibacterial effect and representative bacteria, yeast, and mold is shown in Table 5 below for five types.

strain Strain number Minimum growth inhibitory concentration (MIC) MPG (%) DPG (%) TPG (%) PGP mix
(㎍/㎖) Gram negative bacteria Escherichia coli KCTC 1682 10 7.5 7.5 4 Pseudomonas aeruginosa KCTC 1637 7.5 5 5 16 Gram positive bacteria Staphylococcus aureus KCTC 1621 20 20 20 16 Yeast Candida albicans ATCC MYA-2876 10 7.5 7.5 16 Fungi Aspergillus niger KACC 40277 10 15 15 8

As can be seen in Table 5, as a result of measuring the antibacterial effect of three types of propylene glycol, it showed the best antibacterial activity against Pseudomonas aeruginosa, and was weak compared to other strains against Staphylococcus aureus , but only by 20%. The MIC value was found to be in the range. It can be seen that the Pennybacillus elgi CWL-10 culture broth extract shows a minimum growth inhibition concentration of 4 to 16 ㎍/㎖, showing very strong antibacterial activity compared to propylene glycol.

Example 7. Evaluation of antibacterial activity in cosmetic formulations

To evaluate the antibacterial activity in the cosmetic formulation, the antibacterial activity in the essence cosmetic formulation was confirmed as shown in Table 5. The strains used were E. coli, S. aureus, P. aeruginosa, and C. albicans. The essence formulation was made into a formulation without preservatives (- PGPmix) and a formulation with CWL-10 culture fluid extract as a preservative (+ PGPmix). Each strain was inoculated into ^two essence formulations at a bacterial count of 2 is shown in Figures 6 to 9.

division Raw material Content (100g) alcoholic Ethanol 3 PEG-60Hydrogenated Castor Oil 0.4 PEG-40Hydrogenated Castor Oil 0.1 incense 0.2 Awards Water Up to 100 Carbomer (2%) 10 Xanthan Gum (1%) 20 Glycerin 3 Betaine One Trehalose One Butylene Glycol 3 Propanediol 3 Hyaluronic acid (1%) 7 D-Panthenol 2 Allantoin 0.1 Niacinamide 2 PGPmix 100ppm DPG 2 EDTA-3Na (5%) 0.02 Tromethamine 2.4

As can be seen in Figure 6, as a result of inoculating E. coli at a bacterial count of ²

As can be seen in Figure 7, as a result of inoculating S. aureus at a bacterial count of ²

As can be seen in Figure 8, P. aeruginosa was inoculated at ² It was confirmed that all bacteria were killed in formulations containing PGPmix.

As can be seen in Figure 9, as a result of inoculating Candida albicans at ²

Korea Research Institute of Bioscience and Biotechnology Biological Resources Center KCTC14835BP 20211220

Claims (12)

Paenibacillus elgii strain with antibacterial and antifungal activity. The strain of claim 1, wherein the strain is a Pennybacillus elgi strain deposited as KCTC 14835BP. The strain according to claim 1, wherein the 16s rRNA of the strain includes the base sequence of SEQ ID NO: 3. An antibacterial or antifungal composition comprising Pennybacillus elgium culture medium as an active ingredient. The composition according to claim 4, wherein the strain is a Pennybacillus elgi strain deposited as KCTC 14835BP. The composition according to claim 4, wherein the 16s rRNA of the strain includes the base sequence of SEQ ID NO: 3. The composition of claim 4, wherein the composition contains a pelgipeptin-based compound. The composition of claim 7, wherein the pelgipeptin-based compound is in a linear form, a cyclic form, or a mixture thereof. The method of claim 7, wherein the pelgipeptin-based compound is Pelgipeptin A, Pelgipeptin B, Pelgipeptin C, Pelgipeptin D, and Pelgipeptin E. ), a composition that is one or more selected from the group consisting of. 5. The method of claim 4, wherein the composition comprises benzoic acid and para-hydroxybenzoic acid, their esters and salts, benzyl benzoate, propionic acid and salts thereof. , salicylic acid and its salts, sorbic acid (2,4-hexadienoic acid) and its salts, levulinic acid and its salts, anisic acid and its salts, perylic acid ( perillic acid and its salts, cinnamic acid and its salts, caprylhydroxamic acid, sorbohydroxamic acid, and mixtures thereof. A composition further comprising: The method of claim 4, wherein the composition includes 1,3-propanediol, methyl propanediol, 1,2-pentanediol, and 1,2-hexane. Diol (1,2-hexanediol), 1,2-octanediol (1,2-octanediol), 1,2-decanediol (1,2-decanediol), 1,5-pentanediol (1,5-pentanediol) , 1,6-hexanediol, 1,8-octanediol, 1,2-decanediol, ethylhexylglycerin, Sorbitan caprylate, triclosan, climbazole, chitosan, farnesol, 2-butyloctanoic acid, 2-benzylheptane- 1-ol (2-Benzylheptan-1-ol), glycerol monolaurate, thymol, eugenol, benzyl alcohol, 2-phenyethyl alcohol ), 3-phenyl propanol, 2-phenoxyethanol, 1-phenoxy-propan-2-ol, 3-phenoxy A composition further comprising at least one selected from the group consisting of propanol (3-phenoxypropanol) and benzyloxymethanol. The method of claim 4, wherein the composition further comprises at least one selected from the group consisting of Iturin, Bacillomycin, Fengycin, Surfactin, and lipopeptide. A composition comprising: